Literature DB >> 2969933

Quantitative assessment of interleukin-2-producing alloreactive human T cells by limiting dilution analysis.

J Jooss1, B Zanker, H Wagner, D Kabelitz.   

Abstract

A limiting dilution (LD) culture system was developed to estimate the frequency of IL-2 producing alloantigen-reactive human helper T lymphocytes (HTL). E rosette-purified T cells or cell sorter-separated CD4+ and CD8+ subsets were co-cultured under LD conditions with irradiated allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines (LCL) in the absence of additional growth factors. IL-2 in microculture supernatants was detected in a bioassay combined with rapid colorimetric visualization (cleavage of MTT). Under these conditions, one out of 250-800 E+, 180-280 CD4+, and 440-1000 CD8+ T cells produced IL-2 after a culture period of 3 days. This quantitative analysis of alloantigen-specific human HTL is complete within 4 days and thus provides a rapid method with potential applications in various clinical situations, e.g., transplantation medicine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969933     DOI: 10.1016/0022-1759(88)90037-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

Review 1.  Perspectives in transplantation immunology 1991.

Authors:  D Kabelitz; M L da Silva Lobo; K Pechhold
Journal:  Klin Wochenschr       Date:  1991-09-03

2.  Selective activation of gamma/delta + T cell clones by single anti-CD2 antibodies.

Authors:  S Wesselborg; O Janssen; K Pechhold; D Kabelitz
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

3.  A novel subset of CD2-, CD3/T cell receptor alpha/beta+ human peripheral blood T cells. Phenotypic and functional characterization of interleukin 2-dependent CD2-CD3+ T cell clones.

Authors:  D Kabelitz; P Conradt; S Schondelmaier; H Wagner; R Haars
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.